Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Medtronic
McKesson
Boehringer Ingelheim
AstraZeneca

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Aspen Global Inc Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for ASPEN GLOBAL INC, and what generic and branded alternatives to ASPEN GLOBAL INC drugs are available?

ASPEN GLOBAL INC has ten approved drugs.



Summary for Aspen Global Inc
US Patents:0
Tradenames:8
Ingredients:9
NDAs:10
Drug Master File Entries: 1

Drugs and US Patents for Aspen Global Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aspen Global Inc HEXADROL dexamethasone sodium phosphate INJECTABLE;INJECTION 014694-002 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial
Aspen Global Inc HEXADROL dexamethasone TABLET;ORAL 012675-009 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Aspen Global Inc DECA-DURABOLIN nandrolone decanoate INJECTABLE;INJECTION 013132-002 Jun 12, 1986 DISCN No No   Start Trial   Start Trial
Aspen Global Inc LEUKERAN chlorambucil TABLET;ORAL 010669-002 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial
Aspen Global Inc HEXADROL dexamethasone TABLET;ORAL 012675-010 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Aspen Global Inc ORGARAN danaparoid sodium INJECTABLE;INJECTION 020430-001 Dec 24, 1996 DISCN No No   Start Trial   Start Trial
Aspen Global Inc THIOGUANINE thioguanine TABLET;ORAL 012429-001 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Aspen Global Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Aspen Global Inc ORGARAN danaparoid sodium INJECTABLE;INJECTION 020430-001 Dec 24, 1996 5,164,377   Start Trial
Aspen Global Inc CYCLESSA desogestrel; ethinyl estradiol TABLET;ORAL-28 021090-001 Dec 20, 2000 4,628,051   Start Trial
Aspen Global Inc CYCLESSA desogestrel; ethinyl estradiol TABLET;ORAL-28 021090-001 Dec 20, 2000 4,616,006   Start Trial
Aspen Global Inc CYCLESSA desogestrel; ethinyl estradiol TABLET;ORAL-28 021090-001 Dec 20, 2000 4,544,554   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
McKesson
Boehringer Ingelheim
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.